Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of a new approach to outcome modeling in patients with bladder cancer that undergo a blue light cystoscopy (BLC ®) in ...

OSLO, Norway, Oct. 15, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop ...

OSLO, Norway, Oct. 16, 2020 /PRNewswire/ -- Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC ...

Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with ...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--The KARL STORZ Photodynamic Diagnosis (PDD) System - Blue Light Cystoscopy with Cysview (BLCC) is one of the medical innovations that was showcased in front of ...

MedStar Washington Hospital Center now offers Blue Light Cystoscopy with Cysview®, a new, FDA-approved technology used to pinpoint bladder tumors in patients with known or suspected bladder cancer.

Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in ...

Photodynamic diagnosis (PDD) exploits the photoactive nature of certain compounds in order to enhance the visual demarcation between normal and neoplastic tissue. These agents accumulate ...

Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in ...